CR20140464A - Compuestos de heterociclilo - Google Patents

Compuestos de heterociclilo

Info

Publication number
CR20140464A
CR20140464A CR20140464A CR20140464A CR20140464A CR 20140464 A CR20140464 A CR 20140464A CR 20140464 A CR20140464 A CR 20140464A CR 20140464 A CR20140464 A CR 20140464A CR 20140464 A CR20140464 A CR 20140464A
Authority
CR
Costa Rica
Prior art keywords
compounds
heterociclyl
heteroaryl compounds
tautomers
combinations
Prior art date
Application number
CR20140464A
Other languages
English (en)
Spanish (es)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CR20140464A publication Critical patent/CR20140464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
CR20140464A 2012-03-14 2014-10-06 Compuestos de heterociclilo CR20140464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051915 WO2013136254A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds

Publications (1)

Publication Number Publication Date
CR20140464A true CR20140464A (es) 2014-11-28

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20140463A CR20140463A (es) 2012-03-14 2014-10-06 Compuestos de heterociclilo como inhibidores de mek
CR20140464A CR20140464A (es) 2012-03-14 2014-10-06 Compuestos de heterociclilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20140463A CR20140463A (es) 2012-03-14 2014-10-06 Compuestos de heterociclilo como inhibidores de mek

Country Status (35)

Country Link
US (5) US9428499B2 (en:Method)
EP (2) EP2834236B1 (en:Method)
JP (3) JP6093384B2 (en:Method)
KR (4) KR102241111B1 (en:Method)
CN (4) CN104203947A (en:Method)
AP (2) AP3834A (en:Method)
AU (4) AU2013234009B2 (en:Method)
BR (1) BR112014022713B1 (en:Method)
CA (2) CA2865164C (en:Method)
CL (2) CL2014002412A1 (en:Method)
CO (2) CO7160029A2 (en:Method)
CR (2) CR20140463A (en:Method)
CU (2) CU24335B1 (en:Method)
DK (2) DK2834237T3 (en:Method)
DO (2) DOP2014000203A (en:Method)
EA (2) EA028232B1 (en:Method)
ES (2) ES2741896T3 (en:Method)
GE (2) GEP201706774B (en:Method)
GT (2) GT201400195A (en:Method)
IL (2) IL234560A (en:Method)
IN (2) IN2014MN01755A (en:Method)
MA (2) MA37405A1 (en:Method)
MX (3) MX355474B (en:Method)
MY (2) MY175950A (en:Method)
NI (2) NI201400108A (en:Method)
NZ (2) NZ629442A (en:Method)
PE (2) PE20141973A1 (en:Method)
PH (2) PH12014502040B1 (en:Method)
PL (1) PL2834237T3 (en:Method)
SG (2) SG11201405007QA (en:Method)
TN (2) TN2014000356A1 (en:Method)
TR (1) TR201811976T4 (en:Method)
UA (2) UA114906C2 (en:Method)
WO (2) WO2013136254A1 (en:Method)
ZA (1) ZA201406186B (en:Method)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK2834237T3 (en) 2012-03-14 2018-08-27 Lupin Ltd HETEROCYCLYL COMPOUNDS AS MEK INHITORS
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
EP3061747B1 (en) * 2013-10-25 2021-04-07 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN110167928A (zh) 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10829487B2 (en) * 2017-12-21 2020-11-10 Boehringer Ingelheim International Gmbh Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220249492A1 (en) 2019-06-19 2022-08-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220106106A (ko) * 2019-07-30 2022-07-28 에드빈세 아베 뇌졸중 치료용 mek 억제제
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN115835908A (zh) 2019-10-14 2023-03-21 因赛特公司 作为fgfr抑制剂的双环杂环
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230212164A1 (en) * 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117479942A (zh) 2021-04-09 2024-01-30 勃林格殷格翰国际有限公司 抗癌疗法
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
IL307673A (en) * 2021-04-16 2023-12-01 Ikena Oncology Inc MEK inhibitors and their use
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4441055A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441051A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
EP4441054A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN119013272A (zh) 2021-12-01 2024-11-22 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
TW202511268A (zh) 2023-05-30 2025-03-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之螺環狀2-胺基-3-氰基噻吩及衍生物
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
ME00230B (me) * 2002-01-22 2011-02-10 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101912400B (zh) * 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
BRPI0925050A2 (pt) 2009-04-21 2015-08-04 Novartis Ag Compostos heterocíclicos como inibidores de mek
DK2834237T3 (en) 2012-03-14 2018-08-27 Lupin Ltd HETEROCYCLYL COMPOUNDS AS MEK INHITORS

Also Published As

Publication number Publication date
BR112014022713A2 (en:Method) 2017-06-20
NZ629432A (en) 2017-01-27
ES2684517T3 (es) 2018-10-03
AU2017200493B2 (en) 2018-03-29
KR102240101B1 (ko) 2021-04-14
MA37400B1 (fr) 2019-11-29
CU24335B1 (es) 2018-04-03
PE20141974A1 (es) 2014-12-12
NI201400108A (es) 2014-11-28
MA37405A1 (fr) 2016-03-31
NI201400107A (es) 2014-11-26
PH12014502041B1 (en) 2014-11-24
PH12014502040A1 (en) 2014-11-24
TN2014000357A1 (en) 2015-12-21
ZA201406186B (en) 2016-06-29
EP2834236A1 (en) 2015-02-11
WO2013136254A1 (en) 2013-09-19
NZ629442A (en) 2016-12-23
EA201491671A1 (ru) 2014-12-30
EA028232B1 (ru) 2017-10-31
CN107698585A (zh) 2018-02-16
MA37400A1 (fr) 2016-05-31
US9827247B2 (en) 2017-11-28
PL2834237T3 (pl) 2018-11-30
CO7170131A2 (es) 2015-01-28
US20150299186A1 (en) 2015-10-22
AU2013234009B2 (en) 2016-10-27
GT201400196A (es) 2017-09-28
MX2014010925A (es) 2015-04-10
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
PE20141973A1 (es) 2014-12-12
EP2834236B1 (en) 2019-05-22
US20170112840A1 (en) 2017-04-27
MY174188A (en) 2020-03-12
IL234559A (en) 2017-06-29
US9969731B2 (en) 2018-05-15
KR20140138910A (ko) 2014-12-04
EA029768B1 (ru) 2018-05-31
CN108383836B (zh) 2021-11-12
AU2013234009A1 (en) 2014-09-25
IN2014MN01754A (en:Method) 2015-07-03
CN104203947A (zh) 2014-12-10
AP2014008009A0 (en) 2014-10-31
DK2834237T3 (en) 2018-08-27
CA2865164A1 (en) 2013-09-19
CN104271577A (zh) 2015-01-07
CA2865164C (en) 2021-06-08
MX355474B (es) 2018-04-16
IL234560A (en) 2017-06-29
CL2014002412A1 (es) 2015-03-06
AU2017200493A1 (en) 2017-02-16
US20160331753A1 (en) 2016-11-17
SG11201405007QA (en) 2014-10-30
GEP201706774B (en) 2017-11-27
EP2834237B1 (en) 2018-06-06
GT201400195A (es) 2017-11-09
UA114907C2 (uk) 2017-08-28
DOP2014000203A (es) 2015-02-15
KR20140138911A (ko) 2014-12-04
CN108383836A (zh) 2018-08-10
PH12014502040B1 (en) 2014-11-24
CU20140109A7 (es) 2014-11-27
CA2865167C (en) 2019-08-06
UA114906C2 (uk) 2017-08-28
HK1206020A1 (en) 2015-12-31
US9428499B2 (en) 2016-08-30
AP3834A (en) 2016-09-30
MX355526B (es) 2018-04-20
DK2834236T3 (da) 2019-08-26
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
US9573944B2 (en) 2017-02-21
TR201811976T4 (tr) 2018-09-21
US20170101408A1 (en) 2017-04-13
AU2018202568B2 (en) 2019-05-09
BR112014022713B1 (pt) 2021-09-08
SG11201405006PA (en) 2014-10-30
ES2741896T3 (es) 2020-02-12
AP3859A (en) 2016-10-31
JP6630771B2 (ja) 2020-01-15
AP2014008008A0 (en) 2014-10-31
JP2015514056A (ja) 2015-05-18
PH12014502041A1 (en) 2014-11-24
JP6093384B2 (ja) 2017-03-08
JP6431770B2 (ja) 2018-11-28
GEP201706671B (en) 2017-05-25
KR102241111B1 (ko) 2021-04-15
US20150133424A1 (en) 2015-05-14
DOP2014000204A (es) 2015-02-15
KR20190073597A (ko) 2019-06-26
EP2834237A1 (en) 2015-02-11
AU2018202568A1 (en) 2018-05-10
CL2014002411A1 (es) 2015-04-06
CA2865167A1 (en) 2013-09-19
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
CU20140110A7 (es) 2014-11-27
IN2014MN01755A (en:Method) 2015-07-03
CU24272B1 (es) 2017-08-08
AU2013234014A1 (en) 2014-09-25
WO2013136249A1 (en) 2013-09-19
US9555035B2 (en) 2017-01-31
AU2013234014B2 (en) 2017-02-02
KR20190100472A (ko) 2019-08-28
JP2015509975A (ja) 2015-04-02
MX366426B (es) 2019-07-08
JP2018115215A (ja) 2018-07-26
MX2014010928A (es) 2015-04-10

Similar Documents

Publication Publication Date Title
CR20140464A (es) Compuestos de heterociclilo
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
CR20150045A (es) Inhibidores de hepatitis c
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
CR20150061A (es) Compuesto de pirazolopirimidinas
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CR20150250A (es) Nuevos derivados de piridina
CR20140132A (es) Derivados de pirrolopirimidina y purina
UY34472A (es) Derivados modificados de 4-fenil-piridina
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34523A (es) Derivados de betulina
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20150447A (es) Nuevos derivados de pirazol
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
CR20150204A (es) Nuevos derivados de piridina
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY36073A (es) ?2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS?.
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
PE20151145A1 (es) Piridopirazinas sustituidas como inhibidores de syk
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina